Profile data is unavailable for this security.
About the company
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.
- Revenue in USD (TTM)0.00
- Net income in USD-11.25m
- Incorporated1994
- Employees5.00
- LocationEnveric Biosciences Inc245 FIRST STREET RIVERVIEW II 18TH FLOORCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 444-8400
- Fax+1 (732) 243-9254
- Websitehttps://www.enveric.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azitra Inc | 0.00 | -11.12m | 2.66m | 12.00 | -- | 0.4043 | -- | -- | -5.49 | -5.49 | 0.00 | 0.4066 | 0.00 | -- | -- | 0.00 | -157.91 | -- | -203.88 | -- | -- | -- | -- | -- | -- | -- | 0.1197 | -- | -98.91 | -- | 29.05 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 2.74m | 5.00 | -- | 0.5228 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.85m | 2.74m | 8.00 | -- | 0.2452 | -- | -- | -28.37 | -28.37 | 0.00 | 4.69 | 0.00 | -- | -- | 0.00 | -150.49 | -136.32 | -203.36 | -201.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -57.64 | -- | -- | -- |
| Vaccinex Inc | 601.00k | -18.63m | 2.76m | 23.00 | -- | -- | -- | 4.59 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| Propanc Biopharma Inc | 0.00 | -67.00m | 2.89m | 1.00 | -- | 0.2345 | -- | -- | -13.54 | -13.54 | 0.00 | 0.851 | 0.00 | -- | -- | 0.00 | -869.88 | -- | -1,782.95 | -- | -- | -- | -- | -- | -- | -74.43 | 0.0492 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 3.13m | 5.00 | -- | 0.1421 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Hcw Biologics Inc | 422.03k | -22.21m | 3.17m | 36.00 | -- | -- | -- | 7.50 | -13.96 | -13.96 | 0.2716 | -0.8038 | 0.0162 | -- | 1.24 | 11,723.06 | -46.35 | -53.89 | -- | -66.10 | 20.00 | -- | -2,855.77 | -545.79 | -- | -42.26 | 1.45 | -- | -9.68 | -- | -20.12 | -- | -29.10 | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.26m | 21.00 | -- | -- | -- | 29.11 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| Clearside Biomedical, Inc | 3.33m | -26.00m | 3.38m | 32.00 | -- | -- | -- | 1.02 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Galera Therapeutics Inc | 0.00 | -8.99m | 3.40m | 3.00 | -- | -- | -- | -- | -0.1302 | -0.1302 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -129.27 | -96.94 | -145.04 | -116.42 | -- | -- | -- | -- | -- | -- | 34.30 | -- | -- | -- | 67.91 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.29m | 3.42m | 2.00 | -- | -- | -- | -- | -0.0098 | -0.0098 | 0.00 | -0.0005 | 0.00 | -- | -- | -- | -86,374.50 | -28,790.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.80 | -- | -- | -- |
| Oragenics Inc | 0.00 | -10.90m | 3.47m | 3.00 | -- | 0.3491 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 3.47m | 17.00 | -- | 0.3777 | -- | 1.03 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| National Graphite Corp | 0.00 | -1.97m | 3.55m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Enveric Biosciences Inc's reporting currency: US Dollar USD
22.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ayrton Capital LLCas of 30 Sep 2025 | 292.06k | 21.01% |
| AdvisorShares Investments LLCas of 31 Dec 2025 | 16.97k | 1.22% |
| UBS Securities LLCas of 31 Dec 2025 | 2.89k | 0.21% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 2.28k | 0.16% |
| Tower Research Capital LLCas of 31 Dec 2025 | 1.92k | 0.14% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 51.00 | 0.00% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 49.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 5.00 | 0.00% |
| Group One Trading LLCas of 31 Dec 2025 | 1.00 | 0.00% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 1.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 23 Feb 2026Source: FactSet Research Systems Inc.
